Abstract
Promising Novel Approaches for Metastatic HER2-Overexpressing Breast Cancer Progressing on Trastuzumab: (1) Pertuzumab+Trastuzumab Active after Failed Sequential Therapy; (2) Adding Lapatinib & Continuing Trastuzumab Better than Lapatinib Alone, Reinforcing Trastuzumab Use Beyond Progression; (3) Trastuzumab+Ridaforolimus Effective in Heavily Pretreated Patients; (4) T-DM1 Shrinks Tumors after Multiple Previous Treatments
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
